Support and Resistance Levels
Past performance
About Dishman Carbogen Amcis Ltd Dishman Carbogen Amcis Limited operates in the Contract Research and Manufacturing Services (CRAMS) industry, focusing on specialty chemicals, vitamins, and disinfectants, with a global footprint in Europe, China, and India. The company has a history of strategic mergers and acquisitions aimed at business consolidation and expanding its market reach, notably merging with Dishman Pharmaceuticals and Chemicals Limited in 2017. It has expanded its manufacturing and research capabilities across Switzerland, UK, France, and China, supporting its growth strategy.
The company emphasizes five key therapeutic areas: oncology, ophthalmic, cardiovascular, CNS, and orphan drugs, aiming to meet unmet medical needs. It has significantly enhanced its CRAMS segment, benefiting from its Swiss subsidiary Carbogen Amcis AG's capacity expansion. Dishman has also streamlined its operations through global restructuring and diversification into niche markets. Recent developments include restarting API production, advancing manufacturing facilities, and increasing its focus on high-value, low-volume orders, positioning the company for sustained growth in the pharmaceutical manufacturing sector.